Warner-Lambert is also developing an EGFR inhibitor. EGFR inhibitors are considered amongst the most promising new cancer treatments under development. Based on our solid financial status and the encouraging clinical trial data for this compound, we are in a very strong position to accelerate development of this promising product to the benefit of both our shareholders and the cancer community. In order to minimize any development delays and ensure a smooth transition Pfizer continues to coordinate the ongoing Phase II trials in ovarian, head and neck and non-small cell lung cancer through a transition period of up to six months. Pfizer will also provide OSI Pharmaceuticals with its inventories of finished product, bulk drug and production intermediates.
Sufficient inventories are available to complete an extensive clinical development program.